Compare ING Groep NV (ING) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ING Groep NV vs Viatris Inc — how do they compare? ING Groep NV trades at $32.9 (market cap $92.65B), while Viatris Inc trades at $17 (market cap $19.79B). The key difference: ING Groep NV is far larger — about 4.7× Viatris Inc's market cap, and ING Groep NV pays the higher dividend (3.93%). Which is the better fit depends on your goals.
| ING | VTRS | |
|---|---|---|
Market Cap | $92.65B | $19.79B |
Sector | Financials | Health |
52-Week High | $33.31 | $17.39 |
52-Week Low | $22.71 | $8.74 |
Dividend Yield | 3.93% | 2.83% |
Enterprise Value | — | $32.00B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ING trades at $32.13, down 0.62% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q1 2026 EPS of $0.63, beating expectations of $0.60, continuing a trend of earnings beats. Revenue for 2025 reached $22.90 billion with a net income margin of 27.84%. Recent strategic moves include a stake acquisition in Spain's Singular Bank and the rollout of a global subscription banking model to diversify revenue streams.
The outlook for ING is positive, supported by strong analyst consensus with 62.5% buy ratings and intrinsic value estimates around $34 from DCF analysis. Opportunities include European banking sector strength and net interest income upside from potential ECB rate hikes. Key risks involve persistent negative operating cash flow trends and competitive pressures in digital banking. The stock appears fairly valued with a P/E of 12.96 and P/B of 1.6.
Viatris (VTRS) trades at $17.10, down 1.1% today but maintains a bullish technical outlook with strong moving average signals. The company shows mixed fundamentals with recent earnings beats but negative profitability metrics, while analyst consensus leans toward Hold with a $20 price target. Recent positive developments include FDA acceptance of new drug applications and pipeline progress in biosimilars.
Viatris presents a value opportunity with reasonable P/S and P/B ratios, but faces challenges with negative margins and high debt. The stock's upside potential depends on successful pipeline execution and debt reduction, while risks include competitive pressures and execution missteps in a challenging pharmaceutical market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
